Probiotic bacterial strains producing antimicrobial proteins and compositions comprising these for use in the treatment of diarrheal and other microbial diseases
OwnerFederico GRAFinventor
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a bacterial, preferably probiotic bacterial peptidoglycan hydrolase (PGH), a peptidoglycan hydrolase (PGH)-including bacterial, preferably probiotic bacterial strain or a peptidoglycan hydrolase (PGH)-including composition for use in the therapeutic or prophylactic treatment of a bacterial infection, preferably for the treatment of a bacterial infection resulting in diarrhea. Further aspects of the present invention relate to corresponding methods for preparing a medicament and to a corresponding method of treatment.
Claims14
A method for the prophylaxis and/or treatment of a bacterial infection in a patient in need of such treatment or prophylaxis, the method comprising administering an effective amount of a peptidoglycan hydrolase (PGH), wherein the PGH is a polypeptide selected from:
- (a) polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 89 to 151 and 158 to 163;
- (b) polypeptides comprising an amino acid sequence having an amino acid sequence identity of at least 70 or 80% with an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 89 to 151 and 158 to 163;
- and
- (c) functional fragments or functional derivatives of (a) or (b),
- wherein the method effectuates the prophylaxis and/or treatment of a bacterial infection in the patient.
A method for the prophylaxis and/or treatment of a bacterial infection in a patient in need of such treatment or prophylaxis, the method comprising administering an effective amount of a peptidoglycan hydrolase (PGH), wherein the PGH is encoded by a nucleic acid comprising or consisting of a nucleic acid sequence selected from:
- (a) nucleic acid sequences selected from the group consisting of SEQ ID NOs:
- 1 to 11, 24 to 53, 65 to 81, 84 to 88 and 152 to 157;
- (b) nucleic acid sequences having at least 80 or 90% identity with a nucleic acid sequence listed in SEQ ID NOs:
- 1 to 11, 24 to 53, 65 to 81, 84 to 88 and 152 to 157;
- (c) nucleic acid sequences that hybridize to a nucleic acid sequence of (a) or (b) under stringent conditions;
- (d) fragments of any of the nucleic acid sequences (a) to (c), that hybridize to a nucleic acid sequence of (a) or (b) under stringent conditions;
- and
- (e) a nucleic acid sequence, wherein said nucleic acid sequence is derivable by substitution, addition and/or deletion of one of the nucleic acids of (a) to (d) that hybridizes to a nucleic acid sequence of (a) or (b) under stringent conditions,
- wherein the method effectuates the prophylaxis and/or treatment of a bacterial infection in the patient.
Dependencies are inferred from the claim text.